{"type":"trials","record":{"id":41494,"source_id":"clinicaltrials-gov","external_id":"NCT03577041","title":"Medico-economic Evaluation of Anti-VEGF Treatments in the Treatment of naïve Age-related Macular Degeneration (AMD): a Model Adapted to the French Context","brief_summary":"Age-related macular degeneration (AMD) is the leading cause of blindness after 50 years in industrialized countries, compromising daily activities and reducing quality of life. And whose treatment is one of the first health expenditures. Since September 2015, Bevacizumab, which does not have marketing authorization in AMD, has been given a temporary recommendation for use. Studies in other countries have shown that bevacizumab is cost-effective in the treatment of AMD compared to other anti-VEGF therapies used.","overall_status":"Recruiting","phases":[],"study_type":"OBSERVATIONAL","sponsor":"Centre Hospitalier Universitaire, Amiens","enrollment":600,"countries":["France"],"start_date":"2020-01-29","completion_date":"2026-06-01","last_update_date":"2026-06-15","source_url":"https://clinicaltrials.gov/study/NCT03577041","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"MEDIAL","age_range":"18 Years to 70 Years","comparator":null,"organization":"Centre Hospitalier Universitaire, Amiens","interventions":[],"registry_source":"ClinicalTrials.gov","outcome_measures":["Cost-utility analysis of the modalities of management of neovascular age-related macular degeneration — 12 months","Micro-costing type evaluation of packaging of Intravitreal injections of Bevacizumab in pharmacy hospital. — 12 months","Quality of life coefficient: HUI 3 questionnaire — 12 months"],"design_description":null,"source_has_results":false},"controlled_terms":["Age-related Macular Degeneration (AMD)"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct03577041","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2020-01-29 to 2026-06-01","comparator":null,"confidence":"structured-source","population":"ALL · 18 Years to 70 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.822Z","intervention":[],"participants":600,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Cost-utility analysis of the modalities of management of neovascular age-related macular degeneration — 12 months","Micro-costing type evaluation of packaging of Intravitreal injections of Bevacizumab in pharmacy hospital. — 12 months","Quality of life coefficient: HUI 3 questionnaire — 12 months"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41494","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}